Study wrapper · #1170
Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.
Editor's note
The headline here is dose: these results came from 0.5 to 1.0 mg weekly, well below the 2.4 mg used in the STEP obesity trials, yet the 24-week losses are respectable. That will interest readers following the low-dose question, though this is an observational cohort of just over 100 completers, with no comparator arm and lifestyle counselling running alongside. The subgroup signal, blunted response with diabetes or intrapancreatic fat, echoes patterns seen in larger datasets and is worth watching.
Plain-language abstract
In a real-world Chinese cohort, adults with obesity taking semaglutide at lower maintenance doses (0.5 or 1.0 mg weekly) lost an average of 9.9% of body weight over 24 weeks, and about three in four lost at least 5%. People with type 2 diabetes or fat deposits in the pancreas lost noticeably less than those without.